Adial Pharmaceuticals, Inc. ADIL
Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) is a GI/hepatology drug developer. Its lead program, AT177, is in Pre-clinical for ulcerative colitis. Its next catalyst on record is AT177: IND filing (Q2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AT177 — IND filing (Q2 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AD04 | alcohol use disorder (genetic subgroups) | small molecule | Phase 3 |
| AT177 | ulcerative colitis | small molecule | Pre-clinical |
| AT177 | Crohn's disease | small molecule | Pre-clinical |
| Undisclosed platform program | — | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.